Early Stage In Vitro Bioprofiling of Potential Low-Molecular-Weight Organoboron Compounds for Boron Neutron Capture Therapy (BNCT)-Proposal for a Guide.
BNCT
bioprofiling
boron carriers
drug development
in vitro methods
pre-clinical testing
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
05
03
2024
revised:
24
04
2024
accepted:
03
05
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
24
5
2024
Statut:
epublish
Résumé
Given the renewed interest in boron neutron capture therapy (BNCT) and the intensified search for improved boron carriers, as well as the difficulties of coherently comparing the carriers described so far, it seems necessary to define a basic set of assays and standardized methods to be used in the early stages of boron carrier development in vitro. The selection of assays and corresponding methods is based on the practical experience of the authors and is certainly not exhaustive, but open to discussion. The proposed tests/characteristics: Solubility, lipophilicity, stability, cytotoxicity, and cellular uptake apply to both low molecular weight (up to 500 Da) and high molecular weight (5000 Da and more) boron carriers. However, the specific methods have been selected primarily for low molecular weight boron carriers; in the case of high molecular weight compounds, some of the methods may need to be adapted.
Identifiants
pubmed: 38786022
pii: cells13100798
doi: 10.3390/cells13100798
pii:
doi:
Substances chimiques
Boron Compounds
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Center
ID : 2015/16/W/ST5/00413
Organisme : Ministry of Science and Higher Education
ID : POL-OPENSCREEN (decision no. DIR/WK/2018/06 of October 24, 2018)